Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992706 | 0.92 | CYP1A2 (0.49) | MAOBMAOARAB9AALDH1A1MAPT | |
| SCHEMBL21991595 | 0.88 | MAOB (0.55) | MAOBMAOANR4A2FFAR1NPC1 | |
| SCHEMBL21991942 | 0.88 | CYP1A2 (0.46) | MAOBMAOARAB9AALDH1A1MAPT | |
| SCHEMBL21991981 | 0.87 | MAOB (0.53) | MAOBMAOANR4A2FFAR1NPC1 | |
| SCHEMBL21991340 | 0.86 | LMNA (0.52) | MAOBMAOANR4A2ALDH1A1MAPT | |
| SCHEMBL24418991 | 0.85 | CYP1A2 (0.42) | MAOBMAOAFFAR1CYP1A2 | |
| SCHEMBL21991959 | 0.85 | NPC1 (0.49) | MAOBMAOANR4A2NPC1RAB9A | |
| SCHEMBL21992009 | 0.85 | NR4A2 (0.58) | MAOBMAOANR4A2FFAR1NPC1 | |
| SCHEMBL21991855 | 0.85 | MAOB (0.53) | MAOBMAOANR4A2FFAR1NPC1 | |
| SCHEMBL21992732 | 0.84 | MAOB (0.56) | MAOBFFAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885MAOA 3996/4885NR4A2 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.